Matthias Pfisterer Drug-eluting stents and their additional benefit to low-risk patients were investigated in a cost-effectiveness analysis presented to the Stockholm cardiology meeting by Matthias Pf
Matthias Pfisterer
Drug-eluting stents and their additional benefit to low-risk patients were investigated in a cost-effectiveness analysis presented to the Stockholm cardiology meeting by Matthias Pfisterer from Basel. Audio Medica talked with him.
[audio:https://www.audiomedica.com/podcasting/14.Matt_Pfisterer-Drug-eluting_stents_may_confer_so_little_additional_benefit_to_low_risk_patients.mp3]